
FNCH
Healthcare · Biotechnology · $14.8M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · 30-day revisions 0 up, 1 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2024 | Time not confirmed | — | -3.01 | — |
| May 10, 2024 | After the close | — | -2.41 | — |
| Mar 25, 2024 | After the close | — | -1.89 | — |
| Nov 8, 2023 | Before the open | — | -1.51 | — |
| Aug 10, 2023 | Before the open | -4.50 | -3.24 | +28.0% |
| May 10, 2023 | Before the open | -0.09 | -0.38 | -322.2% |
| Mar 23, 2023 | After the close | -0.34 | -0.56 | -64.7% |
| Nov 10, 2022 | Before the open | -0.40 | -0.85 | -112.5% |
| Aug 11, 2022 | Before the open | -0.41 | -0.48 | -17.1% |
| May 16, 2022 | Before the open | — | -0.52 | — |
| Mar 31, 2022 | After the close | -0.32 | -0.40 | -25.0% |
| Nov 10, 2021 | Before the open | -0.42 | -0.21 | +50.0% |
| Aug 10, 2021 | Before the open | -0.28 | -0.32 | -14.3% |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including…
| May 13, 2021 | Before the open | -0.24 | -1.00 | -316.7% |
| Jan 9, 2021 | After the close | 0.00 | -0.28 | — |